Identifier | 20240306_nanos_surgical1_01 |
Title | TED: Strabismus - When and How to Operate |
Creator | Madhura A Tamhankar, MD |
Affiliation | Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania |
Subject | Thyroid Eye Disease; Restrictive Strabismus; Diplopia; Teprotumumab; Strabismus Surgery |
Description | Restrictive strabismus with diplopia occurs in 30-50% of patients in thyroid eye disease (TED) due to a decrease in muscle fiber elasticity caused by the direct infiltration of inflammatory cells, related to cytokines and eventually fibrosis of the extra ocular muscle1. Impairment of motility occurs significantly more often in smokers and older patients2. Several extraocular muscles may be affected although single unilateral muscle involvement can also occur. Hypertropia with restricted elevation due to inferior rectus involvement and esotropia with restricted abduction from medial rectus involvement are the most common types of restrictive strabismus in TED3. The lateral rectus and the oblique muscles are the least affected. Early in the process most patients typically adopt a chin-up posture due to a tight inferior rectus muscle. New onset diplopia can also occur after orbital decompression because of changes in muscle pads and orbital anatomy. Esotropia is most common after medial orbital wall decompression due to displacement of the medial recti muscles in the ethmoid sinus. |
Date | 2024-03 |
References | 1. Bahn RS. Graves' ophthalmopathy. N Engl J Med. Feb 25;362(8):726-38, 2010. 2. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. Oct;12(10):855-60, 2002. 3. Dyer JA. The oculorotary muscles in Graves' disease. Trans Am Ophthalmol Soc. 74:425-56, 1976. 4. Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Teprotumumab Efficacy, Safety, and Durability in Longer- Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Ophthalmology. Apr;129(4):438-449, 2022. 5. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. Jan 23;382(4):341-352, 2020. |
Language | eng |
Format | application/pdf |
Format Creation | Microsoft PowerPoint |
Type | Text |
Source | 2024 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of | NANOS Annual Meeting 2024: Surgical Challenges in Neuro-Ophthalmology |
Collection | Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
Publisher | North American Neuro-Ophthalmology Society |
Holding Institution | Spencer S. Eccles Health Sciences Library, University of Utah |
Rights Management | Copyright 2024. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK | ark:/87278/s6ycp8qk |
Setname | ehsl_novel_nam |
ID | 2593114 |
Reference URL | https://collections.lib.utah.edu/ark:/87278/s6ycp8qk |